The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study

BACKGROUND: Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marrow niche. STUDY DESIGN AND METHODS: in the prospective HOVON‐107 study (www.hovon.nl) 23 allogeneic HLA–identical sibling donors received one or two subc...

Descripción completa

Detalles Bibliográficos
Autores principales: de Greef, Georgine E., Braakman, Eric, van der Holt, Bronno, Janssen, Jeroen J.W.M., Petersen, Eefke, Vucinic, Vladimir, Thuss, Nicole, Grootes, Meriam, Cornelissen, Jan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Cellular Therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380058/
https://www.ncbi.nlm.nih.gov/pubmed/30548284
http://dx.doi.org/10.1111/trf.15037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380058/
https://www.ncbi.nlm.nih.gov/pubmed/30548284
http://dx.doi.org/10.1111/trf.15037

Ejemplares similares